首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi

市場調查報告書

商品編碼

1127250

mRNA癌症治療的專利格局分析（2022）

mRNA Cancer Therapies Patent Landscape Analysis 2022

出版日期: 2022年09月20日 | 出版商:

KnowMade | 英文 100 Slide PDF, Excel File - 570 patent families | 商品交期: 最快1-2個工作天內

價格

簡介目錄

目前正在進行 600 多項 mRNA 臨床試驗，而且這個數字還在繼續增長，這反映了公司日益增長的興趣和經濟利益。然而，迄今為止，市場上還沒有產品，儘管已經針對主要專利發起了幾項專利挑戰。這裡已經確定了大約 20 項異議程序，其中大部分是在過去五年中提出的，並且仍在等待中。

了解其他公司的知識產權地位和戰略在不斷變化的環境中至關重要。這些知識使我們能夠感知業務風險和機遇，預測新技術並做出戰略決策以加強我們的市場地位。

本報告調查了癌症 mRNA 療法的專利格局，並提供了諸如已公佈專利的時間變化、專利申請國家、專利法律狀態等知識產權趨勢以及主要公司概況等信息。

本報告中提到的公司

BioNTech、Cellectis、CoImmune、CureVac、eTheRNA immunotherapies、Factor Bioscience、Gritstone bio、ImmunityBio、Moderna、Myeloid Therapeutics、諾華、RIKEN、賽諾菲、上海泰利生物、Tricision Biotechnology、Nutcracker Therapeutics、Orna Therapeutics等

p> >

內容

簡介

mRNA，癌症治療的新領域
調查範圍
主要專利申請人

調查方法

搜索、選擇和分析專利
搜索策略
專利分析術語
強度和阻斷潛力

執行摘要

專利格局概覽

發佈時間轉換
申請國家/地區的時間變化
最多專利申請人的排名
主要公司的當前法律地位
語料庫專利法律地位
當前主要 IP 所有者的映射
一家領先的知識產權公司的專利活動
主要專利申請人隨時間的變化

新進入者

創業公司
成立公司

合作

主申請人IP位置

專利申請人的知識產權領導力
知識產權現有技術阻止專利申請人
專利組合實力指數
主要專利

對 EP 的主要反對意見

專利細分

定義
按技術：專利家族數量
主要申請人技術
跨矩陣段
特定的 RNA 類型：circRNA
特定的 RNA 類型：saRNA
RNA 修飾和穩定化
載體：聚合物
載體：脂質
給藥途徑：腫瘤
給藥途徑：腸胃外
治療：抗體
療法：免疫調節劑
治療：AG 直流負載
療法：直接注射AG
治療：修飾抗原受體

主要公司的知識產權概況

BioNTech
TRON
CureVac
Moderna
Novartis
University of Pennsylvania

結論

已知的演示文稿

聯繫方式

簡介目錄

Product Code: KM22004

Report's Key Features:

PDF > 100 slides

Excel database containing all patents analyzed in the report (>570 patent families), including patent segmentations and hyperlinks to an updated online database.

IP trends, including time evolution of published patents, countries of patent filings and patents' legal status

Ranking of main patent assignees

Key players' IP position and relative strength of their patent portfolios

Summary of the IP related to RNAs and carriers: specific RNA type (circRNA, saRNA), RNA modification & stabilization, carriers (vesicle, virus, peptide, polymer, lipid).

Summary of the IP related to treatment: antibody, immuno-modulator, antigen (direct or via DC), modified antigen receptor.

Analysis of collaboration and EP patent oppositions.

Context of the report

For nearly three decades, extensive efforts have been made to increase RNA intracellular stability, translational efficiency and uptake of mRNA. Several players have taken an interest in this issue, such as mRNA technology leaders CureVac, Moderna and BioNTech. These optimizations were achieved by modifying RNA non-coding elements (5' cap, 5'- and 3'- UTRs, 3' poly-A tail) and RNA coding region, and through the development of formulation technologies with specific carriers. In cancer immunotherapy, the most advanced application of mRNA is therapeutic vaccination with mRNA encoding antigens, i.e., direct cancer vaccines or dendritic cell vaccines. Moreover, for more than a decade, industrialists and academics have been developing personalized cancer vaccines, based on the specific molecular features of patients' tumors, to elicit an immune response against neoantigens produced by cancer cells. Other applications of mRNA in cancer immunotherapy include engineering T cells with modified antigen receptors such as CAR-T, immunomodulator production such as cytokines, co-stimulatory ligands and receptors, and antibody delivery. Currently, there are more than 600 clinical trials in progress, and this number continues to increase, reflecting the growing interest in this topic as well as the economic stakes for companies. However, to date, there is still no product on the market, but several patent oppositions have already been initiated against key patents. Around 20 opposition proceedings have been identified herein, most of which were filed in the past five years and still pending. By winning the race for the Covid-19 vaccine, mRNA vaccines have proven their worth, and demonstrated that RNA-based therapies can deliver on their promises. Additionally, it highlighted the advantages of mRNA over conventional therapies: active at a relatively low dose range, can be developed rapidly, and GMP-compliant manufacturing processes easily upscaled for rapid availability of large numbers of doses. All progress made in the development of Covid-19 vaccines will certainly help advance the development of mRNA-based cancer therapies. In this evolving context, it is crucial to understand the intellectual property position and strategy of these different players. Such knowledge can help detect business risks and opportunities, anticipate emerging technologies, and enable strategic decisions to strengthen market position.

Analysis of the time evolution of patent publications shows that mRNA cancer therapies started to be investigated in 1992, but the technology emerged in the early 2000s with European companies such as CureVac and BioNTech, and American Universities such as Johns Hopkins University, Duke University and Texas University. In 2015 and 2017, two peaks are observed, resulting in an increase in the number of patent applicants. Moreover, in 2017, Moderna published 11 patent families and CureVac 7 patent families. As of 2019, this trend continues. Indeed, the increase in patent publications mainly corresponds to an increase in the number of assignees rather than an increase in the number of patent families for a player, even if BioNTech published 15 then 11 patent families in 2020 and 2021 respectively.

Analysis by segment

mRNA cancer therapies have been investigated and the selected patent families labeled according to the technologies to which they relate. This IP landscape features the following five types of segmentation: specific RNA type (circRNA, saRNA), RNA modification & stabilization, carriers (vesicle, virus, peptide, polymer, lipid), delivery route (tumoral, parenteral, other) and therapy (mRNA encoded antibody, immunomodulator, antigen via DC loading, antigen via direct injection, modified antigen receptor).

EP oppositions

There is a significant number of EP oppositions, which reflects the strategic issues of mRNA cancer therapies for companies. Most of the proceedings are recent, filed in the past five years, and are still pending. For each opposed patent, the application date, assignee, opponent, opposition year and results are detailed.

Identifying the companies that have recently emerged in the IP landscape

Among the players owning patent families related to mRNA cancer therapies, 50 newcomers were identified. These companies are either start-up firms (20) or established companies (30) developing their first technology in the mRNA field. These technologies are mainly related to carriers or to mRNA encoded specific proteins. Numerous IP newcomers are based in the US and in Asia, while some are based in Europe. It is possible that one of these innovative companies could become one of the next healthcare unicorns that the big corporations will be tempted to acquire.

IP profile of key players

This IP study includes a selection and description of the key players. The patent portfolio analysis of key players includes a description of the assignee, key numbers in terms of patents, time evolution of patent publication, main geographical coverage and live patents by technical segment. This IP profile overview is followed by the description of all the assignee's key patents and by a table with its clinical trials.

Moreover, the report also includes an Excel database with the 574 patent families analyzed in this study. This useful patent database allows for multi-criteria searches and includes patent publication numbers, hyperlinks to the original documents, priority dates, titles, abstracts, patent assignees, each patent's current legal status and segmentation.

Companies mentioned in this report (non-exhaustive list)

BioNTech, Cellectis, CoImmune, CureVac, eTheRNA immunotherapies, Factor Bioscience, Gritstone bio, ImmunityBio, Moderna, Myeloid Therapeutics, Novartis, RIKEN, Sanofi, Shanghai Telebio Biomedical, Tricision Biotechnology, Nutcracker Therapeutics, Orna Therapeutics, etc.